The ruling means that small-scale compounders must immediately stop making their versions of Novo’s Ozempic and Wegovy, while ...

The court ruled in favor of Novo Nordisk and the FDA, rejecting a compounding pharmacy group's attempt to stop the FDA's ...

Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment ...

Novo Nordisk scored a legal win against compounders of its blockbuster GLP-1 drugs. But it may not end the copycats.

Novo Nordisk filed for approval of an oral, 25-mg formulation of its weight loss blockbuster “earlier this year,” according ...

Patients flocked to those Ozempic, Wegovy copycats when the branded drugs were in short supply, or if they didn’t have ...

A spokesperson confirmed the Danish drugmaker has asked U.S. regulators to clear an oral version of its weight loss drug ...

However, making it will require Novo Nordisk to ramp up semaglutide production even further. Citing a Novo spokesperson, pharmaceuticals news site BioPharmaDive reported yesterday that Novo ...

Based on SOUL findings, Novo Nordisk submitted a label extension ... stroke and CV death in those treated with oral semaglutide vs placebo. The proven cardiovascular benefit reflects a profound ...

PLAINSBORO, N.J., April 14, 2025 /PRNewswire/ -- Novo Nordisk has become aware of several hundred units of Ozempic ® (semaglutide) injection 1 mg distributed outside the Novo Nordisk authorized ...

Novo Nordisk ... yesterday that Novo Nordisk "earlier this year" submitted to the Food and Drug Administration an application to approve an oral form of its semaglutide GLP-1 weight loss drug.